New news: Detailed explanation of Germany’s trastuzumab drug donation policy

Fam-trastuzumab deruxtecan-nxki, marketed under the trade name Enhertu, is an innovative antibody drug conjugate (ADC) that targets HER2 (human epidermal growth factor receptor 2) for precise treatment. This drug uniquely combines an anti-HER2 antibody with a cytotoxic drug to accurately identify and destroy HER2-overexpressing tumor cells. Trastuzumab undoubtedly brings new hope to patients with HER2-positive breast cancer and other HER2-overexpressing solid tumors, especially those who have failed to respond to traditional treatments.

However, facing high treatment costs will increase the financial burden for many patients and their families. Fortunately, pharmaceutical companies and related charities often offer a variety of drug grants and patient assistance programs to help financially disadvantaged patients obtain necessary treatments. The drug donation policy for trastuzumab varies by region, national policy, and patient population. Generally, these policies are designed to ensure that eligible patients have access to this life-saving medication at a reduced cost or completely free of charge. Some pharmaceutical companies may partner with medical institutions, charitable organizations, or government departments to launch various forms of patient support programs.

These programs may include direct drug discounts, copay assistance, free drug supplies, and more. In addition, participating in clinical trials is a way to obtain free medical treatment. Pharmaceutical companies often invite patients who meet certain criteria to participate in clinical trials to evaluate the efficacy and safety of new drugs. In return, patients who participate in clinical trials often receive the investigational drug as well as related medical services and monitoring at no cost.